Mycosis fungoides diagnostic study of choice: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
 
(7 intermediate revisions by the same user not shown)
Line 3: Line 3:
{{CMG}}; {{AE}} {{S.G.}}
{{CMG}}; {{AE}} {{S.G.}}
== Overview ==
== Overview ==
Mycosis fungoides is primarily diagnosed based on the clinical presentation.
Mycosis fungoides is primarily [[Diagnosis|diagnosed]] based on the [[clinical]] presentation.


== Diagnostic Study of Choice ==
== Diagnostic Study of Choice ==


Mycosi fungoides must be performed when:<ref name="pmid20568590">{{cite journal |vauthors=Galper SL, Smith BD, Wilson LD |title=Diagnosis and management of mycosis fungoides |journal=Oncology (Williston Park, N.Y.) |volume=24 |issue=6 |pages=491–501 |date=May 2010 |pmid=20568590 |doi= |url=}}</ref>
*Mycosi fungoides must be performed when:<ref name="pmid20568590">{{cite journal |vauthors=Galper SL, Smith BD, Wilson LD |title=Diagnosis and management of mycosis fungoides |journal=Oncology (Williston Park, N.Y.) |volume=24 |issue=6 |pages=491–501 |date=May 2010 |pmid=20568590 |doi= |url=}}</ref>
* The patient presents with symptomatic progressive skin lesions such as: patches, plaques, tumors, and erytheroderma, and a poorer prognosis in later stages.
**Mycosis fungoides is primarily diagnosed based on the [[clinical]] presentation.
**The [[patient]] presents with [[symptomatic]] progressive [[skin]] [[Lesion|lesions]] such as: [[Patched|patches]], [[Plaque|plaques]], [[Tumor|tumors]], and [[erythroderma]], and a poorer [[prognosis]] in later stages.
**There is no single [[Diagnosis|diagnostic]] study of choice for the [[diagnosis]] of mycosis fungoides, and mycosis fungoides can be [[Diagnosis|diagnosed]] difficult by nonspecific [[skin]] presentation.
**[[Disease]] present with [[skin]] [[Lesion|lesions]] not treated by useual [[medication]].


* There is no single diagnostic study of choice for the diagnosis of mycosis fungoides, and mycosis fungoides can be diagnosed difficult by nonspecific skin presentation.
*[[Diagnosis]] [[Criterion|criteria]] from the International Society for [[Cutaneous]] [[Lymphoma]] is:<ref name="FossGirardi2017" /><ref name="PimpinelliOlsen2005">{{cite journal|last1=Pimpinelli|first1=Nicola|last2=Olsen|first2=Elise A.|last3=Santucci|first3=Marco|last4=Vonderheid|first4=Eric|last5=Haeffner|first5=Andreas C.|last6=Stevens|first6=Seth|last7=Burg|first7=Guenter|last8=Cerroni|first8=Lorenzo|last9=Dreno|first9=Brigitte|last10=Glusac|first10=Earl|last11=Guitart|first11=Joan|last12=Heald|first12=Peter W.|last13=Kempf|first13=Werner|last14=Knobler|first14=Robert|last15=Lessin|first15=Stuart|last16=Sander|first16=Christian|last17=Smoller|first17=Bruce S.|last18=Telang|first18=Gladys|last19=Whittaker|first19=Sean|last20=Iwatsuki|first20=Keiji|last21=Obitz|first21=Erik|last22=Takigawa|first22=Masahiro|last23=Turner|first23=Maria L.|last24=Wood|first24=Gary S.|title=Defining early mycosis fungoides|journal=Journal of the American Academy of Dermatology|volume=53|issue=6|year=2005|pages=1053–1063|issn=01909622|doi=10.1016/j.jaad.2005.08.057}}</ref>
* Lesions disease present with skin lesions not treated by useual medication.<ref name="pmid20568590" />
* Mycosis fungoides is primarily diagnosed based on the clinical presentation.


==Staging==
{| class="wikitable"
|+
! style="background: #4479BA; color:#FFF;" |Criteria
! style="background: #4479BA; color:#FFF;" |Major( 2pinots)
! style="background: #4479BA; color:#FFF;" |Minor(1point)
|-
|'''Persistent and/or progressive patches and plaques plus'''
|Any 2
|Any 1
|-
| colspan="3" style="background: #B0C4DE; color:#FFF;" ! |Clinical
|-
|1. Non–sun-exposed location
|
|
|-
|2.Size/shape variation
|
|
|-
|3.Poikiloderma
|
|
|-
| colspan="3" style="background: #B0C4DE; color:#FFF;" ! |'''Histopathologic'''
|-
|Superficial lymphoid infiltrate plus
|Both
|Either
|-
|1. Epidermotropism
|
|
|-
|2. [[Atypia]]
|
|
|-
| colspan="3" style="background: #B0C4DE; color:#FFF;" ! |'''Molecular/biological'''
|-
|Clonal [[TCR]] [[gene]] [[rearrangement]]
|
|Present
|-
| colspan="3" style="background: #B0C4DE; color:#FFF;" ! |'''Immunopathologic'''
|-
|1. [[CD2]], [[CD3]], [[CD5]] in <59% of [[T cell|T cells]]
|
|Any 1
|-
|2. [[CD7]] in <10% of [[T cell|T cells]]
|
|
|-
| colspan="3" |3. [[Epidermis (skin)|Epidermal]] discordance from [[expression]] of [[CD2]], [[CD3 (immunology)|CD3]], [[CD5]], and [[CD7]] on [[dermal]] [[T cell|T cells]]
|}


==References==
==References==
{{Reflist|2}}
{{Reflist|2}}

Latest revision as of 16:41, 12 February 2019

Mycosis fungoides Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Mycosis Fungoides from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

X-Ray

CT Scan

MRI

Echocardiography and Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Mycosis fungoides diagnostic study of choice On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Mycosis fungoides diagnostic study of choice

All Images
X-rays
Echo and Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Mycosis fungoides diagnostic study of choice

CDC on Mycosis fungoides diagnostic study of choice

Mycosis fungoides diagnostic study of choice in the news

Blogs on Mycosis fungoides diagnostic study of choice

Directions to Hospitals Treating Mycosis fungoides

Risk calculators and risk factors for Mycosis fungoides diagnostic study of choice

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]

Overview

Mycosis fungoides is primarily diagnosed based on the clinical presentation.

Diagnostic Study of Choice

Criteria Major( 2pinots) Minor(1point)
Persistent and/or progressive patches and plaques plus Any 2 Any 1
Clinical
1. Non–sun-exposed location
2.Size/shape variation
3.Poikiloderma
Histopathologic
Superficial lymphoid infiltrate plus Both Either
1. Epidermotropism
2. Atypia
Molecular/biological
Clonal TCR gene rearrangement Present
Immunopathologic
1. CD2, CD3, CD5 in <59% of T cells Any 1
2. CD7 in <10% of T cells
3. Epidermal discordance from expression of CD2, CD3, CD5, and CD7 on dermal T cells

References

  1. ↑ Galper SL, Smith BD, Wilson LD (May 2010). "Diagnosis and management of mycosis fungoides". Oncology (Williston Park, N.Y.). 24 (6): 491–501. PMID 20568590.
  2. ↑
  3. ↑ Pimpinelli, Nicola; Olsen, Elise A.; Santucci, Marco; Vonderheid, Eric; Haeffner, Andreas C.; Stevens, Seth; Burg, Guenter; Cerroni, Lorenzo; Dreno, Brigitte; Glusac, Earl; Guitart, Joan; Heald, Peter W.; Kempf, Werner; Knobler, Robert; Lessin, Stuart; Sander, Christian; Smoller, Bruce S.; Telang, Gladys; Whittaker, Sean; Iwatsuki, Keiji; Obitz, Erik; Takigawa, Masahiro; Turner, Maria L.; Wood, Gary S. (2005). "Defining early mycosis fungoides". Journal of the American Academy of Dermatology. 53 (6): 1053–1063. doi:10.1016/j.jaad.2005.08.057. ISSN 0190-9622.
Retrieved from "https://www.wikidoc.org/index.php?title=Mycosis_fungoides_diagnostic_study_of_choice&oldid=1549087"